Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matteo Quartagno

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
Journal of Clinical Epidemiology|October 1, 2025
A Bayesian framework to evaluate noninferiority in randomized controlled trials of uncommon conditionsVictoria R Cornelius, Jack Elkes, Ian R White, et al.
BMJ (Clinical Research Ed.)|June 17, 2024
Exploring different objectives in non-inferiority trialsConor D Tweed, Matteo Quartagno, Michelle N Clements, et al.
Journal of Psychosomatic Research|September 10, 2020
Different independent associations of depression and anxiety with survival in patients with cancerJane Walker, Nicholas Magill, Amy Mulick, et al.
Cancers|November 27, 2021
Excess Mortality by Multimorbidity, Socioeconomic, and Healthcare Factors, amongst Patients Diagnosed with Diffuse Large B-Cell or Follicular Lymphoma in EnglandMatthew James Smith, Aurélien Belot, Matteo Quartagno, et al.
Statistics in Medicine|January 20, 2023
Practical approaches to Bayesian sample size determination in non-inferiority trials with binary outcomesRebecca M Turner, Michelle N Clements, Matteo Quartagno, et al.
PLOS Global Public Health|July 19, 2024
Treatment preferences among people at risk of developing tuberculosis: A discrete choice experimentWala Kamchedzera, Matthew Quaife, Wezi Msukwa-Panje, et al.
Psychosomatic Medicine|May 3, 2021
Major Depression and Survival in People With CancerJane Walker, Amy Mulick, Nicholas Magill, et al.
The Lancet. Oncology|May 3, 2025
Determining the optimal use of approved drugs in oncologyGauthier Bouche, Duncan Gilbert, Matteo Quartagno, et al.
NEJM Evidence|August 15, 2022
Improving clinical trial interpretation with ACCEPT analysesMichelle N Clements, Ian R White, Andrew J Copas, et al.
The Lancet. Oncology|May 4, 2023
REFINE-Lung implements a novel multi-arm randomised trial design to address possible immunotherapy overtreatmentEhsan Ghorani, Matteo Quartagno, Fiona Blackhall, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Journal of Clinical Epidemiology|October 1, 2025
A Bayesian framework to evaluate noninferiority in randomized controlled trials of uncommon conditionsVictoria R Cornelius, Jack Elkes, Ian R White, et al.
BMJ (Clinical Research Ed.)|June 17, 2024
Exploring different objectives in non-inferiority trialsConor D Tweed, Matteo Quartagno, Michelle N Clements, et al.
Journal of Psychosomatic Research|September 10, 2020
Different independent associations of depression and anxiety with survival in patients with cancerJane Walker, Nicholas Magill, Amy Mulick, et al.
Cancers|November 27, 2021
Excess Mortality by Multimorbidity, Socioeconomic, and Healthcare Factors, amongst Patients Diagnosed with Diffuse Large B-Cell or Follicular Lymphoma in EnglandMatthew James Smith, Aurélien Belot, Matteo Quartagno, et al.
Statistics in Medicine|January 20, 2023
Practical approaches to Bayesian sample size determination in non-inferiority trials with binary outcomesRebecca M Turner, Michelle N Clements, Matteo Quartagno, et al.
PLOS Global Public Health|July 19, 2024
Treatment preferences among people at risk of developing tuberculosis: A discrete choice experimentWala Kamchedzera, Matthew Quaife, Wezi Msukwa-Panje, et al.
Psychosomatic Medicine|May 3, 2021
Major Depression and Survival in People With CancerJane Walker, Amy Mulick, Nicholas Magill, et al.
The Lancet. Oncology|May 3, 2025
Determining the optimal use of approved drugs in oncologyGauthier Bouche, Duncan Gilbert, Matteo Quartagno, et al.
NEJM Evidence|August 15, 2022
Improving clinical trial interpretation with ACCEPT analysesMichelle N Clements, Ian R White, Andrew J Copas, et al.
The Lancet. Oncology|May 4, 2023
REFINE-Lung implements a novel multi-arm randomised trial design to address possible immunotherapy overtreatmentEhsan Ghorani, Matteo Quartagno, Fiona Blackhall, et al.
Pageof 6